Compare Abeona Therapeutics Inc (ABEO) vs Home Depot Inc (HD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Home Depot Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Home Depot Inc trades at $335.36 (market cap $344.21B). The key difference: Home Depot Inc is far larger — about 922× Abeona Therapeutics Inc's market cap, and Home Depot Inc pays a 2.7% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | HD | |
|---|---|---|
Market Cap | $373.32M | $344.21B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $423.42 |
52-Week Low | $4.17 | $297.51 |
Enterprise Value | $228.22M | $405.77B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Home Depot (HD) trades at $336.21, down 4.12% on the day, with a bullish technical signal from moving averages despite recent weakness. The stock shows strong profitability with 8.41% net margin and 128.38% ROE, though Q3 2025 EPS missed expectations. Revenue grew to $159.51B in 2025, but net income margin has trended down from 10.87% in 2022. Recent news highlights institutional activity and concerns over housing market headwinds from rising mortgage rates.
Outlook remains supported by analyst consensus with 59% buy ratings and $370.59 price target, but risks include weakening big-ticket demand and margin pressure. The stock offers a dividend yield with recent $2.33 payment, while long-term growth depends on Pro segment performance and housing market recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →
